Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver

Gene Therapy

Volumn 10, Issue 18, 2003, Pages 1551-1558

  Loiler, S A ^a,b,c   Conlon, T J ^a,b,c   Song, S ^a,b,c   Tang, Q ^a,b,c   Warrington Jr , K H ^a,b,c   Agarwal, A ^a,b,c   Kapturczak, M ^a,b,c   Li, C ^a,b,c   Ricordi, C ^a,b,c   Atkinson, M A ^a,b,c   Muzyczka, N ^a,b,c   Flotte, T R ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Diabetes; Targeting

Indexed keywords

APOLIPOPROTEIN; LIGAND; LOW DENSITY LIPOPROTEIN RECEPTOR; PARVOVIRUS VECTOR; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL TYPE; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; LIVER CELL; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SEROTYPE; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; APOLIPOPROTEINS E; CELLS, CULTURED; DEPENDOVIRUS; DIABETES MELLITUS, TYPE 1; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; ISLETS OF LANGERHANS; LIVER; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MURINAE; PARVOVIRUS;

EID: 0041375553     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302046     Document Type: Article

References (34)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
2. Carroll PB et al. Long-term (> 3-year) insulin independence in a patient with pancreatic islet cell transplantation following upper abdominal exenteration and liver replacement for fibrolamellar hepatocellular carcinoma. Transplantation 1995; 59: 875-879.
3. Kenyon N et al. Islet transplantation: present and future perspectives. Diabetes Metab Rev 1998; 14: 303-313.
4. Ranuncoli A et al. Islet cell transplantation: in vivo and in vitro functional assessment of nonhuman primate pancreatic islets. Cell Transplant 2000; 9: 409-414.
5. Shapiro AM et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
6. Tahara H et al. Islet cell transplantation facilitated by gene transfer. Transplant Proc 1992; 24: 2975-2976.
7. Flotte T et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes 2001; 50: 515-520.
8. Datta G et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000; 39: 213-220.
9. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
10. Kaludov N et al. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75: 6884-6893.
11. Auricchio A, O'Connor E, Hildinger M, Wilson JM. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther 2001; 4: 372-374.
12. Walters RW et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 276: 20610-20616.
13. Bantel-Schaal U, Hub B, Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol 2002; 76: 2340-2349.
14. Sanlioglu S et al. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 2001; 1: 137-147.
15. Rabinowitz JE et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
16. Wu P et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism [In Process Citation]. J Virol 2000; 74: 8635-8647.
17. Perrey S et al. The LDL receptor is the major pathway for beta-VLDL uptake by mouse peritoneal macrophages. Atherosclerosis 2001; 154: 51-60.
18. Tam SP, Zhang X, Koschinsky ML. Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. J Lipid Res 1996; 37: 518-533.
19. Burgess JW, Marcel YL. Dynamic and stable pools of apoE differ functionally at the HepG2 cell surface. J Lipid Res 2001; 42: 1413-1420.
20. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 1999; 17: 181-186.
21. Grifman M et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964-975.
22. Nicklin SA et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181.
23. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001; 12: 1697-1711.
24. Yang Q et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther 1998; 9: 1929-1937.
25. Yang YW, Kotin RM. Glucose-responsive gene delivery in pancreatic Islet cells via recombinant adeno-associated viral vectors. Pharm Res 2000; 17: 1056-61.
26. Swindle CS, Klug CA. Mechanisms that regulate silencing of gene expression from retroviral vectors. J Hematother Stem Cell Res 2002; 11: 449-456.
27. Prasad Alur RK et al. Modification of multiple transcriptional regulatory elements in a Moloney murine leukemia virus gene transfer vector circumvents silencing in fibroblast grafts and increases levels of expression of the transferred enzyme. Gene Therapy 2002; 9: 1645.
28. Gallichan WS et al. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998; 9: 2717-2726.
29. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184: 1093-1099.
30. Pileggi A et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 2001; 50: 1983-1991.
31. Xu L et al. CMV-beta-actin promoter directs higher expression from an adeno- associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573.
32. McCarty DM, Christensen M, Muzyczka N. Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein. J Virol 1991; 65: 2936-2945.
33. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
34. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.